PD-1 or PD-L1 as First-Line Treatment of Metastatic Gastroesophageal Cancer

In the current issue of JAMA, Zhang and colleagues describe the role of sugemalimab—an anti–programmed death-ligand 1 (anti–PD-L1) monoclonal antibody—in combination with chemotherapy for first-line treatment of metastatic gastric and gastroesophageal junction adenocarcinoma in the phase 3 GEMSTONE-303 trial. Sugemalimab is the first anti–PD-L1 agent to join the busy landscape of immune checkpoint inhibitors in first-line treatment for gastroesophageal junction adenocarcinoma.